nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—ABCG2—Teniposide—lymphatic system cancer	0.209	0.289	CbGbCtD
Leflunomide—ABCG2—Mitoxantrone—lymphatic system cancer	0.146	0.202	CbGbCtD
Leflunomide—CYP1A2—Carmustine—lymphatic system cancer	0.128	0.177	CbGbCtD
Leflunomide—ABCG2—Vincristine—lymphatic system cancer	0.1	0.139	CbGbCtD
Leflunomide—CYP2C9—Teniposide—lymphatic system cancer	0.0775	0.107	CbGbCtD
Leflunomide—ABCG2—Methotrexate—lymphatic system cancer	0.0608	0.0843	CbGbCtD
Leflunomide—Body temperature increased—Fludarabine—lymphatic system cancer	0.000447	0.0016	CcSEcCtD
Leflunomide—Mental disorder—Carmustine—lymphatic system cancer	0.000446	0.0016	CcSEcCtD
Leflunomide—Malnutrition—Carmustine—lymphatic system cancer	0.000443	0.00159	CcSEcCtD
Leflunomide—Cough—Bleomycin—lymphatic system cancer	0.000443	0.00159	CcSEcCtD
Leflunomide—Diarrhoea—Teniposide—lymphatic system cancer	0.00044	0.00158	CcSEcCtD
Leflunomide—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000438	0.00157	CcSEcCtD
Leflunomide—Myalgia—Bleomycin—lymphatic system cancer	0.000433	0.00155	CcSEcCtD
Leflunomide—Chest pain—Bleomycin—lymphatic system cancer	0.000433	0.00155	CcSEcCtD
Leflunomide—Alopecia—Vincristine—lymphatic system cancer	0.00043	0.00154	CcSEcCtD
Leflunomide—Back pain—Carmustine—lymphatic system cancer	0.000429	0.00154	CcSEcCtD
Leflunomide—Discomfort—Bleomycin—lymphatic system cancer	0.000427	0.00153	CcSEcCtD
Leflunomide—Mental disorder—Vincristine—lymphatic system cancer	0.000426	0.00153	CcSEcCtD
Leflunomide—Chills—Mitoxantrone—lymphatic system cancer	0.000425	0.00152	CcSEcCtD
Leflunomide—Neoplasm—Methotrexate—lymphatic system cancer	0.000425	0.00152	CcSEcCtD
Leflunomide—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000425	0.00152	CcSEcCtD
Leflunomide—Bladder pain—Methotrexate—lymphatic system cancer	0.000425	0.00152	CcSEcCtD
Leflunomide—Ecchymosis—Methotrexate—lymphatic system cancer	0.000425	0.00152	CcSEcCtD
Leflunomide—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000423	0.00152	CcSEcCtD
Leflunomide—Alopecia—Mitoxantrone—lymphatic system cancer	0.000418	0.0015	CcSEcCtD
Leflunomide—Vision blurred—Carmustine—lymphatic system cancer	0.000418	0.0015	CcSEcCtD
Leflunomide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000417	0.00149	CcSEcCtD
Leflunomide—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000415	0.00149	CcSEcCtD
Leflunomide—Infection—Bleomycin—lymphatic system cancer	0.000412	0.00148	CcSEcCtD
Leflunomide—Anaemia—Carmustine—lymphatic system cancer	0.00041	0.00147	CcSEcCtD
Leflunomide—Back pain—Vincristine—lymphatic system cancer	0.000409	0.00147	CcSEcCtD
Leflunomide—Vomiting—Teniposide—lymphatic system cancer	0.000409	0.00147	CcSEcCtD
Leflunomide—Sepsis—Methotrexate—lymphatic system cancer	0.000408	0.00146	CcSEcCtD
Leflunomide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000406	0.00145	CcSEcCtD
Leflunomide—Asthenia—Fludarabine—lymphatic system cancer	0.000406	0.00145	CcSEcCtD
Leflunomide—Rash—Teniposide—lymphatic system cancer	0.000406	0.00145	CcSEcCtD
Leflunomide—Dermatitis—Teniposide—lymphatic system cancer	0.000405	0.00145	CcSEcCtD
Leflunomide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000404	0.00145	CcSEcCtD
Leflunomide—Headache—Teniposide—lymphatic system cancer	0.000403	0.00144	CcSEcCtD
Leflunomide—Pruritus—Fludarabine—lymphatic system cancer	0.0004	0.00143	CcSEcCtD
Leflunomide—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.0004	0.00143	CcSEcCtD
Leflunomide—Back pain—Mitoxantrone—lymphatic system cancer	0.000399	0.00143	CcSEcCtD
Leflunomide—Leukopenia—Carmustine—lymphatic system cancer	0.000397	0.00142	CcSEcCtD
Leflunomide—Anorexia—Bleomycin—lymphatic system cancer	0.000395	0.00142	CcSEcCtD
Leflunomide—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000392	0.0014	CcSEcCtD
Leflunomide—Anaemia—Vincristine—lymphatic system cancer	0.000391	0.0014	CcSEcCtD
Leflunomide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000389	0.00139	CcSEcCtD
Leflunomide—Hypotension—Bleomycin—lymphatic system cancer	0.000387	0.00139	CcSEcCtD
Leflunomide—Diarrhoea—Fludarabine—lymphatic system cancer	0.000387	0.00139	CcSEcCtD
Leflunomide—Hypertension—Carmustine—lymphatic system cancer	0.000383	0.00137	CcSEcCtD
Leflunomide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000383	0.00137	CcSEcCtD
Leflunomide—Nausea—Teniposide—lymphatic system cancer	0.000382	0.00137	CcSEcCtD
Leflunomide—Anaemia—Mitoxantrone—lymphatic system cancer	0.000381	0.00137	CcSEcCtD
Leflunomide—Vertigo—Vincristine—lymphatic system cancer	0.00038	0.00136	CcSEcCtD
Leflunomide—Hepatic failure—Methotrexate—lymphatic system cancer	0.00038	0.00136	CcSEcCtD
Leflunomide—Leukopenia—Vincristine—lymphatic system cancer	0.000379	0.00136	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000378	0.00135	CcSEcCtD
Leflunomide—Myalgia—Carmustine—lymphatic system cancer	0.000378	0.00135	CcSEcCtD
Leflunomide—Chest pain—Carmustine—lymphatic system cancer	0.000378	0.00135	CcSEcCtD
Leflunomide—Anxiety—Carmustine—lymphatic system cancer	0.000376	0.00135	CcSEcCtD
Leflunomide—Paraesthesia—Bleomycin—lymphatic system cancer	0.000372	0.00133	CcSEcCtD
Leflunomide—Malaise—Mitoxantrone—lymphatic system cancer	0.000372	0.00133	CcSEcCtD
Leflunomide—Dyspnoea—Bleomycin—lymphatic system cancer	0.00037	0.00132	CcSEcCtD
Leflunomide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000369	0.00132	CcSEcCtD
Leflunomide—Hypertension—Vincristine—lymphatic system cancer	0.000365	0.00131	CcSEcCtD
Leflunomide—Decreased appetite—Bleomycin—lymphatic system cancer	0.00036	0.00129	CcSEcCtD
Leflunomide—Myalgia—Vincristine—lymphatic system cancer	0.00036	0.00129	CcSEcCtD
Leflunomide—Cough—Mitoxantrone—lymphatic system cancer	0.00036	0.00129	CcSEcCtD
Leflunomide—Infection—Carmustine—lymphatic system cancer	0.00036	0.00129	CcSEcCtD
Leflunomide—Vomiting—Fludarabine—lymphatic system cancer	0.00036	0.00129	CcSEcCtD
Leflunomide—Rash—Fludarabine—lymphatic system cancer	0.000357	0.00128	CcSEcCtD
Leflunomide—Dermatitis—Fludarabine—lymphatic system cancer	0.000356	0.00128	CcSEcCtD
Leflunomide—Hypertension—Mitoxantrone—lymphatic system cancer	0.000356	0.00128	CcSEcCtD
Leflunomide—Pain—Bleomycin—lymphatic system cancer	0.000355	0.00127	CcSEcCtD
Leflunomide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000354	0.00127	CcSEcCtD
Leflunomide—Headache—Fludarabine—lymphatic system cancer	0.000354	0.00127	CcSEcCtD
Leflunomide—Tachycardia—Carmustine—lymphatic system cancer	0.000353	0.00127	CcSEcCtD
Leflunomide—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000352	0.00126	CcSEcCtD
Leflunomide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000351	0.00126	CcSEcCtD
Leflunomide—Chest pain—Mitoxantrone—lymphatic system cancer	0.000351	0.00126	CcSEcCtD
Leflunomide—Myalgia—Mitoxantrone—lymphatic system cancer	0.000351	0.00126	CcSEcCtD
Leflunomide—Anxiety—Mitoxantrone—lymphatic system cancer	0.00035	0.00125	CcSEcCtD
Leflunomide—Discomfort—Mitoxantrone—lymphatic system cancer	0.000347	0.00124	CcSEcCtD
Leflunomide—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000345	0.00124	CcSEcCtD
Leflunomide—Anorexia—Carmustine—lymphatic system cancer	0.000345	0.00124	CcSEcCtD
Leflunomide—Infection—Vincristine—lymphatic system cancer	0.000343	0.00123	CcSEcCtD
Leflunomide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000342	0.00122	CcSEcCtD
Leflunomide—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000341	0.00122	CcSEcCtD
Leflunomide—Nervous system disorder—Vincristine—lymphatic system cancer	0.000339	0.00121	CcSEcCtD
Leflunomide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000338	0.00121	CcSEcCtD
Leflunomide—Hypotension—Carmustine—lymphatic system cancer	0.000338	0.00121	CcSEcCtD
Leflunomide—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000336	0.00121	CcSEcCtD
Leflunomide—Nausea—Fludarabine—lymphatic system cancer	0.000336	0.0012	CcSEcCtD
Leflunomide—Infection—Mitoxantrone—lymphatic system cancer	0.000334	0.0012	CcSEcCtD
Leflunomide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000334	0.0012	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00033	0.00118	CcSEcCtD
Leflunomide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000329	0.00118	CcSEcCtD
Leflunomide—Urticaria—Bleomycin—lymphatic system cancer	0.000329	0.00118	CcSEcCtD
Leflunomide—Anorexia—Vincristine—lymphatic system cancer	0.000329	0.00118	CcSEcCtD
Leflunomide—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000328	0.00118	CcSEcCtD
Leflunomide—Body temperature increased—Bleomycin—lymphatic system cancer	0.000328	0.00117	CcSEcCtD
Leflunomide—Insomnia—Carmustine—lymphatic system cancer	0.000327	0.00117	CcSEcCtD
Leflunomide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000327	0.00117	CcSEcCtD
Leflunomide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000325	0.00117	CcSEcCtD
Leflunomide—Paraesthesia—Carmustine—lymphatic system cancer	0.000325	0.00116	CcSEcCtD
Leflunomide—Hypotension—Vincristine—lymphatic system cancer	0.000323	0.00116	CcSEcCtD
Leflunomide—Dyspnoea—Carmustine—lymphatic system cancer	0.000323	0.00116	CcSEcCtD
Leflunomide—Anorexia—Mitoxantrone—lymphatic system cancer	0.000321	0.00115	CcSEcCtD
Leflunomide—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000315	0.00113	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000315	0.00113	CcSEcCtD
Leflunomide—Decreased appetite—Carmustine—lymphatic system cancer	0.000315	0.00113	CcSEcCtD
Leflunomide—Hypotension—Mitoxantrone—lymphatic system cancer	0.000314	0.00113	CcSEcCtD
Leflunomide—Insomnia—Vincristine—lymphatic system cancer	0.000312	0.00112	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000312	0.00112	CcSEcCtD
Leflunomide—Paraesthesia—Vincristine—lymphatic system cancer	0.00031	0.00111	CcSEcCtD
Leflunomide—Pain—Carmustine—lymphatic system cancer	0.000309	0.00111	CcSEcCtD
Leflunomide—Constipation—Carmustine—lymphatic system cancer	0.000309	0.00111	CcSEcCtD
Leflunomide—Breast disorder—Methotrexate—lymphatic system cancer	0.000308	0.0011	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000307	0.0011	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000307	0.0011	CcSEcCtD
Leflunomide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000305	0.00109	CcSEcCtD
Leflunomide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000302	0.00108	CcSEcCtD
Leflunomide—Decreased appetite—Vincristine—lymphatic system cancer	0.0003	0.00108	CcSEcCtD
Leflunomide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.0003	0.00107	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000298	0.00107	CcSEcCtD
Leflunomide—Feeling abnormal—Carmustine—lymphatic system cancer	0.000298	0.00107	CcSEcCtD
Leflunomide—Fatigue—Vincristine—lymphatic system cancer	0.000298	0.00107	CcSEcCtD
Leflunomide—Asthenia—Bleomycin—lymphatic system cancer	0.000297	0.00107	CcSEcCtD
Leflunomide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000296	0.00106	CcSEcCtD
Leflunomide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000296	0.00106	CcSEcCtD
Leflunomide—Pain—Vincristine—lymphatic system cancer	0.000295	0.00106	CcSEcCtD
Leflunomide—Constipation—Vincristine—lymphatic system cancer	0.000295	0.00106	CcSEcCtD
Leflunomide—Asthma—Methotrexate—lymphatic system cancer	0.000295	0.00106	CcSEcCtD
Leflunomide—Pruritus—Bleomycin—lymphatic system cancer	0.000293	0.00105	CcSEcCtD
Leflunomide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000292	0.00105	CcSEcCtD
Leflunomide—Eosinophilia—Methotrexate—lymphatic system cancer	0.000292	0.00105	CcSEcCtD
Leflunomide—Fatigue—Mitoxantrone—lymphatic system cancer	0.00029	0.00104	CcSEcCtD
Leflunomide—Pancreatitis—Methotrexate—lymphatic system cancer	0.000289	0.00104	CcSEcCtD
Leflunomide—Pain—Mitoxantrone—lymphatic system cancer	0.000288	0.00103	CcSEcCtD
Leflunomide—Constipation—Mitoxantrone—lymphatic system cancer	0.000288	0.00103	CcSEcCtD
Leflunomide—Body temperature increased—Carmustine—lymphatic system cancer	0.000286	0.00103	CcSEcCtD
Leflunomide—Abdominal pain—Carmustine—lymphatic system cancer	0.000286	0.00103	CcSEcCtD
Leflunomide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000283	0.00101	CcSEcCtD
Leflunomide—Pancytopenia—Methotrexate—lymphatic system cancer	0.00028	0.001	CcSEcCtD
Leflunomide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000277	0.000993	CcSEcCtD
Leflunomide—Dysuria—Methotrexate—lymphatic system cancer	0.000276	0.000988	CcSEcCtD
Leflunomide—Neutropenia—Methotrexate—lymphatic system cancer	0.000276	0.000988	CcSEcCtD
Leflunomide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000275	0.000986	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000274	0.000982	CcSEcCtD
Leflunomide—Abdominal pain—Vincristine—lymphatic system cancer	0.000273	0.000978	CcSEcCtD
Leflunomide—Body temperature increased—Vincristine—lymphatic system cancer	0.000273	0.000978	CcSEcCtD
Leflunomide—Urticaria—Mitoxantrone—lymphatic system cancer	0.000267	0.000958	CcSEcCtD
Leflunomide—Hypersensitivity—Carmustine—lymphatic system cancer	0.000267	0.000955	CcSEcCtD
Leflunomide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000266	0.000953	CcSEcCtD
Leflunomide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000266	0.000953	CcSEcCtD
Leflunomide—Pneumonia—Methotrexate—lymphatic system cancer	0.000264	0.000947	CcSEcCtD
Leflunomide—Vomiting—Bleomycin—lymphatic system cancer	0.000264	0.000944	CcSEcCtD
Leflunomide—Infestation—Methotrexate—lymphatic system cancer	0.000263	0.000942	CcSEcCtD
Leflunomide—Infestation NOS—Methotrexate—lymphatic system cancer	0.000263	0.000942	CcSEcCtD
Leflunomide—Rash—Bleomycin—lymphatic system cancer	0.000261	0.000937	CcSEcCtD
Leflunomide—Dermatitis—Bleomycin—lymphatic system cancer	0.000261	0.000936	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000261	0.000934	CcSEcCtD
Leflunomide—Asthenia—Carmustine—lymphatic system cancer	0.00026	0.00093	CcSEcCtD
Leflunomide—Renal failure—Methotrexate—lymphatic system cancer	0.000258	0.000926	CcSEcCtD
Leflunomide—Stomatitis—Methotrexate—lymphatic system cancer	0.000256	0.000918	CcSEcCtD
Leflunomide—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000255	0.000915	CcSEcCtD
Leflunomide—Hypersensitivity—Vincristine—lymphatic system cancer	0.000255	0.000912	CcSEcCtD
Leflunomide—Haematuria—Methotrexate—lymphatic system cancer	0.000251	0.000898	CcSEcCtD
Leflunomide—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000249	0.000891	CcSEcCtD
Leflunomide—Epistaxis—Methotrexate—lymphatic system cancer	0.000248	0.000888	CcSEcCtD
Leflunomide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000248	0.000888	CcSEcCtD
Leflunomide—Asthenia—Vincristine—lymphatic system cancer	0.000248	0.000888	CcSEcCtD
Leflunomide—Diarrhoea—Carmustine—lymphatic system cancer	0.000248	0.000887	CcSEcCtD
Leflunomide—Nausea—Bleomycin—lymphatic system cancer	0.000246	0.000882	CcSEcCtD
Leflunomide—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000245	0.000879	CcSEcCtD
Leflunomide—Asthenia—Mitoxantrone—lymphatic system cancer	0.000241	0.000865	CcSEcCtD
Leflunomide—Dizziness—Carmustine—lymphatic system cancer	0.000239	0.000857	CcSEcCtD
Leflunomide—Haemoglobin—Methotrexate—lymphatic system cancer	0.000237	0.00085	CcSEcCtD
Leflunomide—Diarrhoea—Vincristine—lymphatic system cancer	0.000236	0.000847	CcSEcCtD
Leflunomide—Haemorrhage—Methotrexate—lymphatic system cancer	0.000236	0.000845	CcSEcCtD
Leflunomide—Hepatitis—Methotrexate—lymphatic system cancer	0.000236	0.000845	CcSEcCtD
Leflunomide—Pharyngitis—Methotrexate—lymphatic system cancer	0.000234	0.000839	CcSEcCtD
Leflunomide—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000233	0.000835	CcSEcCtD
Leflunomide—Urethral disorder—Methotrexate—lymphatic system cancer	0.000231	0.000829	CcSEcCtD
Leflunomide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00023	0.000825	CcSEcCtD
Leflunomide—Vomiting—Carmustine—lymphatic system cancer	0.00023	0.000824	CcSEcCtD
Leflunomide—Dizziness—Vincristine—lymphatic system cancer	0.000228	0.000819	CcSEcCtD
Leflunomide—Rash—Carmustine—lymphatic system cancer	0.000228	0.000818	CcSEcCtD
Leflunomide—Dermatitis—Carmustine—lymphatic system cancer	0.000228	0.000817	CcSEcCtD
Leflunomide—Headache—Carmustine—lymphatic system cancer	0.000227	0.000812	CcSEcCtD
Leflunomide—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000223	0.000799	CcSEcCtD
Leflunomide—Eye disorder—Methotrexate—lymphatic system cancer	0.000221	0.00079	CcSEcCtD
Leflunomide—Vomiting—Vincristine—lymphatic system cancer	0.00022	0.000787	CcSEcCtD
Leflunomide—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000219	0.000785	CcSEcCtD
Leflunomide—Rash—Vincristine—lymphatic system cancer	0.000218	0.00078	CcSEcCtD
Leflunomide—Dermatitis—Vincristine—lymphatic system cancer	0.000218	0.00078	CcSEcCtD
Leflunomide—Headache—Vincristine—lymphatic system cancer	0.000216	0.000775	CcSEcCtD
Leflunomide—Nausea—Carmustine—lymphatic system cancer	0.000215	0.00077	CcSEcCtD
Leflunomide—Vomiting—Mitoxantrone—lymphatic system cancer	0.000214	0.000766	CcSEcCtD
Leflunomide—Immune system disorder—Methotrexate—lymphatic system cancer	0.000213	0.000764	CcSEcCtD
Leflunomide—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000213	0.000762	CcSEcCtD
Leflunomide—Rash—Mitoxantrone—lymphatic system cancer	0.000212	0.00076	CcSEcCtD
Leflunomide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000212	0.000759	CcSEcCtD
Leflunomide—Chills—Methotrexate—lymphatic system cancer	0.000212	0.000759	CcSEcCtD
Leflunomide—Headache—Mitoxantrone—lymphatic system cancer	0.000211	0.000755	CcSEcCtD
Leflunomide—Alopecia—Methotrexate—lymphatic system cancer	0.000209	0.000747	CcSEcCtD
Leflunomide—Mental disorder—Methotrexate—lymphatic system cancer	0.000207	0.000741	CcSEcCtD
Leflunomide—Malnutrition—Methotrexate—lymphatic system cancer	0.000205	0.000736	CcSEcCtD
Leflunomide—Nausea—Vincristine—lymphatic system cancer	0.000205	0.000735	CcSEcCtD
Leflunomide—Dysgeusia—Methotrexate—lymphatic system cancer	0.000201	0.000721	CcSEcCtD
Leflunomide—Nausea—Mitoxantrone—lymphatic system cancer	0.0002	0.000716	CcSEcCtD
Leflunomide—Back pain—Methotrexate—lymphatic system cancer	0.000199	0.000712	CcSEcCtD
Leflunomide—Vision blurred—Methotrexate—lymphatic system cancer	0.000194	0.000694	CcSEcCtD
Leflunomide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000191	0.000683	CcSEcCtD
Leflunomide—Anaemia—Methotrexate—lymphatic system cancer	0.00019	0.00068	CcSEcCtD
Leflunomide—Malaise—Methotrexate—lymphatic system cancer	0.000185	0.000664	CcSEcCtD
Leflunomide—Vertigo—Methotrexate—lymphatic system cancer	0.000185	0.000661	CcSEcCtD
Leflunomide—Leukopenia—Methotrexate—lymphatic system cancer	0.000184	0.000659	CcSEcCtD
Leflunomide—Cough—Methotrexate—lymphatic system cancer	0.000179	0.000642	CcSEcCtD
Leflunomide—Arthralgia—Methotrexate—lymphatic system cancer	0.000175	0.000627	CcSEcCtD
Leflunomide—Myalgia—Methotrexate—lymphatic system cancer	0.000175	0.000627	CcSEcCtD
Leflunomide—Chest pain—Methotrexate—lymphatic system cancer	0.000175	0.000627	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000174	0.000622	CcSEcCtD
Leflunomide—Discomfort—Methotrexate—lymphatic system cancer	0.000173	0.000619	CcSEcCtD
Leflunomide—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000168	0.000601	CcSEcCtD
Leflunomide—Infection—Methotrexate—lymphatic system cancer	0.000167	0.000597	CcSEcCtD
Leflunomide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000164	0.000589	CcSEcCtD
Leflunomide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000164	0.000588	CcSEcCtD
Leflunomide—Skin disorder—Methotrexate—lymphatic system cancer	0.000163	0.000583	CcSEcCtD
Leflunomide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000162	0.000581	CcSEcCtD
Leflunomide—Anorexia—Methotrexate—lymphatic system cancer	0.00016	0.000572	CcSEcCtD
Leflunomide—Hypotension—Methotrexate—lymphatic system cancer	0.000157	0.000561	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000153	0.000547	CcSEcCtD
Leflunomide—Insomnia—Methotrexate—lymphatic system cancer	0.000152	0.000543	CcSEcCtD
Leflunomide—Paraesthesia—Methotrexate—lymphatic system cancer	0.000151	0.000539	CcSEcCtD
Leflunomide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000149	0.000535	CcSEcCtD
Leflunomide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000148	0.000529	CcSEcCtD
Leflunomide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000146	0.000522	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000145	0.000519	CcSEcCtD
Leflunomide—Fatigue—Methotrexate—lymphatic system cancer	0.000145	0.000518	CcSEcCtD
Leflunomide—Pain—Methotrexate—lymphatic system cancer	0.000143	0.000514	CcSEcCtD
Leflunomide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000138	0.000495	CcSEcCtD
Leflunomide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000137	0.000491	CcSEcCtD
Leflunomide—Urticaria—Methotrexate—lymphatic system cancer	0.000133	0.000477	CcSEcCtD
Leflunomide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000133	0.000475	CcSEcCtD
Leflunomide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000133	0.000475	CcSEcCtD
Leflunomide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000124	0.000442	CcSEcCtD
Leflunomide—Asthenia—Methotrexate—lymphatic system cancer	0.00012	0.000431	CcSEcCtD
Leflunomide—Pruritus—Methotrexate—lymphatic system cancer	0.000119	0.000425	CcSEcCtD
Leflunomide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000115	0.000411	CcSEcCtD
Leflunomide—Dizziness—Methotrexate—lymphatic system cancer	0.000111	0.000397	CcSEcCtD
Leflunomide—Vomiting—Methotrexate—lymphatic system cancer	0.000107	0.000382	CcSEcCtD
Leflunomide—Rash—Methotrexate—lymphatic system cancer	0.000106	0.000379	CcSEcCtD
Leflunomide—Dermatitis—Methotrexate—lymphatic system cancer	0.000106	0.000378	CcSEcCtD
Leflunomide—Headache—Methotrexate—lymphatic system cancer	0.000105	0.000376	CcSEcCtD
Leflunomide—Nausea—Methotrexate—lymphatic system cancer	9.96e-05	0.000357	CcSEcCtD
